This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Hearttransplantation is an effective treatment for end-stage heart disease, and postoperative patients' medication adherence is crucial for transplantation outcomes and long-term survival.
The world's first partial hearttransplant has achieved what researchers have spent more than a year hoping for—functioning valves and arteries that grow along with the young patient, as hypothesized by the pioneering team behind the procedure at Duke Health.
Jon Kobashigawa, MD, of the Smidt Heart Institute at Cedars-Sinai, is an expert in hearttransplantation, heart failure, and other complex cardiac conditions. Kobashigawa was instrumental in expanding the Comprehensive Transplant Program at Cedars-Sinai , one of the largest transplant programs in the world. “Dr.
THE TEXAS HEART INSTITUTE 2024 milla1cf Tue, 02/13/2024 - 17:56 February 13, 2024 — Pediatric hearttransplantation has long been hailed as a life-saving intervention for children suffering from end-stage heart failure. The research, led by esteemed physician-scientist at The Texas Heart Institute ( THI ), Dr. James F.
The risk of early heart failure after hearttransplantation is lower if the donor heart is stored in a so-called heart-in-a-box instead of in the usual cooler with ice. This is according to a study by researchers at the University of Gothenburg.
Philadelphia-based University of Pennsylvania researchers found the number of hearttransplant emergency department visits increased with high admission rates but low in-hospital mortality rates.
Researchers at Atlanta-based Emory University developed artificial intelligence that they say improves the prediction of successful hearttransplants by 10%.
This study aimed to investigate the inhibitory effect of estradiol (E2) on acute cellular rejection following murine cervical hearttransplantation and the role of G protein-coupled estrogen receptor 1 (GPER1).
Having explored how the heart is formed in utero, a researcher is reporting how cells and molecules act during that early formation and what might cause the heart disease called left ventricular non-compaction or spongy heart, for which patients often require hearttransplants.
Adult patients surviving with congenital heart disease (ACHD) is growing. We examine the factors associated with hearttransplant outcomes in this challenging population with complex anatomy requiring redo-sur.
When a patient with heart failure has received a new heart and survives—the transplantation is deemed a success. However, health care overlooks heart recipients who suffer from long-term and often severe symptoms, such as pain and fatigue.
Pretransplant type 2 diabetes mellitus (T2DM) is associated with increased cardiovascular and all-cause mortality after hearttransplant (HT), but the underlying causes of this association remain unclear.
RELIEVE-HF investigators evaluated the efficacy and safety of the V-wave interatrial shunt system in patients with heart failure. The primary endpoint was a composite of all-cause mortality, left ventricular assist device (LVAD)/hearttransplantation, HF hospitalizations, worsening HF, and KCCQ score changes.
As the only pediatric hearttransplant program in Louisiana and the only program in the state to offer advanced mechanical support options for pediatric cardiology patients, Ochsner Children’s Hospital is committed to advocating for additional medical devices to enhance its high-quality care to pediatric patients awaiting transplant.
(MedPage Today) -- To more fairly rank candidates for hearttransplant, researchers developed the U.S. candidate risk score (US-CRS) and found it to better discriminate risk for people with advanced heart failure than the current six-status system.
Food and Drug Adminstration (FDA) has approved DEFINITY (Perflutren Lipid Microsphere) as an ultrasound enhancing agent for use in pediatric patients with suboptimal echocardiograms, including those who have undergone hearttransplant, or have Kawasaki disease or a congenital cardiovascular anomaly. All rights reserved. 4 Fine, N.
Koonlawee Nademanee, Director of the Bumrungrad Heart Institute in Thailand, have spearheaded the establishment of a world-class heart institute. This institute is dedicated to pioneering research, innovation, and the development of clinically effective techniques for addressing various heart conditions.
This study investigates the efficacy of using a long-acting insulin analog, along with the infusion of regular insulin, in achieving appropriate glycemic control and correcting lactic acidosis in patients post.
CV, cardiovascular; HT, hearttransplantation; ICU, intensive care unit; LVAD, left ventricular assist device. The primary endpoint was the rate of weaning from VA-ECMO during index admission. The early LV unloading strategy did not increase the weaning rate from VA-ECMO compared with the conventional approach.
With her fellowship, Dr. Fiedler plans to learn skills and administrative approaches that will help her expand the hearttransplant program at UW-Madison, where she currently serves as associate director of hearttransplantation and mechanical circulatory support. For more information, visit sts.org.
Abstract Aims There is uncertainty about the definition of iron deficiency (ID) and the association between ID and prognosis in patients with advanced heart failure. We evaluated three definitions of ID in patients referred for hearttransplantation.
Correct responses regarding the recommendation class for hearttransplantation were 84%, 55%, and 60% ( p <0.0001), and for MCS as a bridge to transplantation, 69%, 65%, and 55% ( p =0.018) among HFCs, GCs, and OPs, respectively. of HFCs, 19.6% of GCs, and 18.2% of OPs ( p =0.0005).
The secondary outcome was the TE and mortality and hearttransplantation rates between paediatric and adult patients with LVNC. Studies that did not present original research, non-human studies, duplicated studies were excluded. Methods The primary outcome was the prevalence and incidence of TE in the patients with LVNC.
Abstract Aims The CASTLE-HTx trial showed the benefit of atrial fibrillation (AF) ablation compared to medical therapy in decreasing mortality, need for left ventricular assist device implantation or hearttransplantation (HTx) in patients with end-stage heart failure (HF).
The primary composite endpoint included all-cause mortality, hearttransplantation, or ventricular assist device implantation. The secondary endpoint was first heart failure admission. Multivariable Cox regression and propensity score matching (PSM) analyses were performed.
Open-Heart Surgery : In cases where catheterization is not sufficient, open-heart surgery may be required to repair the defect. This involves opening the chest and heart to make the necessary repairs. HeartTransplant : In the most severe cases, where the heart is too damaged to be repaired, a hearttransplant may be necessary.
When patients awaiting crucial hearttransplants are placed on the organ transplant waiting list, they've traditionally been arranged based on what type of treatments they were receiving for their current condition. But researchers from the University of Chicago have discovered a new, more accurate way to rank patients.
Image courtesy of Hideki Kobayashi from Shinshu University milla1cf Tue, 04/30/2024 - 12:53 April 30, 2024 — Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart to recover lost function. However, the risk of arrhythmias following this procedure is reportedly high.
The study also includes a registry for advanced heart failure patients who are end stage and not considered to be surgical candidates for a hearttransplant or left ventricular assist device (LVAD) implant due to excessive fluid retention and poor kidney function. Fain, MD , President and Chief Executive Officer, Procyrion. "We
The primary outcome was all-cause death and hearttransplantation. Secondary heart failure (HF) and arrhythmic outcomes were also included. Methods and results Baseline and follow-up data of first-degree relatives of probands affected by DCM/NDLVC were collected. A total of 492 first degree relatives were enrolled.
The primary outcome was death from any cause, and the secondary outcome included a composite of death, hearttransplantation, or ventricular assist device implantation. At a mean (±SD) follow-up of 40±20 months, CRT showed a significantly lower risk of death or hospitalization due to heart failure.
William Abraham of the Ohio State Wexner College of Medicine presented analysis showing that patients in the trial with Barostim + GDMT had a 74% reduced risk of receiving advanced heart failure interventions (transplant, LVAD, CCM, CRT or CardioMEMS) at long-term follow-up versus patients on GDMT alone. See more details at TCTMD.
Researchers Elizabeth Jordan and Ray Hershberger, MD discuss the results of genetic tests that indicate a risk for dilated cardiomyopathy. The inherited heart condition often goes undiagnosed until it advances to heart failure, which is why it’s important to identify those at risk and begin treatment early.
The CardiAMP clinical development for heart failure is supported by the Maryland Stem Cell Research Fund and is reimbursed by CMS for both treatment and control procedures. The study includes an eligibility requirement that patients demonstrate a pre-specified NT-proBNP level at baseline.
While the trial did not meet its primary endpoint, it moves the field forward by offering signals that the benefits and risks of interatrial shunts may vary by heart failure type, according to researchers. Researchers tracked outcomes in each participant for at least one year and up to two years.
While the trial did not meet its primary endpoint, it moves the field forward by offering signals that the benefits and risks of interatrial shunts may vary by heart failure type, according to researchers. Researchers tracked outcomes in each participant for at least one year and up to two years.
CV mortality is the composite endpoint for CV mortality + urgent transplant + left ventricular assist device implantation. Abstract Aims Improvement of left ventricular ejection fraction is a major goal of heart failure (HF) treatment. Events per 1000 person-years. # ml/min, peak oxygen uptake 62.2
There is increased cognizance of gender inequality and the importance of inclusive and diverse approaches to medical research. Historically, women have been underrepresented in scientific fields, and this spills over into the research and study of women’s health.
For the global rank score all participants were ranked across three hierarchical groups: Tier 1 = time to death or urgent hearttransplantation or implantation of a ventricular assist device; Tier 2 = time to non-fatal HF requiring i.v.
Researchers randomly assigned patients to receive standard care or standard care plus treatment with an Impella CP pump. of those who received the Impella pump had died at six months after randomization; there was a 13 percentage point absolute reduction in the rate of death, the study’s primary endpoint, in favor of the heart pump.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content